In lung cancer, the angiogenic vascular endothelial growth factor (VEGF) is expressed mainly in tumor cells, and bevacizumab, a humanized anti-VEGF monoclonal antibody, has been developed and is applied as systemic therapy in patients with nonsmall cell lung cancer, with the exception of squamous cell carcinoma [34–36]. This evidence concerns the gene VEGFA and squamous cell carcinoma.